Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxycodone hydrochloride controlled-release tablets Clear all
Recruiting Phase 3 Interventional

Opioid-Sparing Joint Replacement

NCT07348627
View directory record Official record
Conditions
Pain Management, Opioid Consumption
Interventions
Placebo, Oxycodone 5 mg, Multimodal Non-Opioid Analgesia
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853892
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 18, 2026, 10:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Opioid Use After Laparoscopic Salpingectomy

NCT06434233
View directory record Official record
Conditions
Opioid Use, Post-operative Pain, Sterility, Female
Interventions
Acetaminophen, Ibuprofen, Oxycodone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Multimodal Pain Control Protocol for Minimally Invasive Gynecologic Surgery

NCT04710277
View directory record Official record
Conditions
Postoperative Pain, Narcotic Use, Cryotherapy Effect
Interventions
Opioid-sparing multimodal pain management, Usual care
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nasal Human Abuse Potential of PTI-821

NCT03475862
View directory record Official record
Conditions
Opioid Abuse Nondependent
Interventions
PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin, Placebo, Oxycodone
Drug · Other
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

NCT01192295
View directory record Official record
Conditions
Pain
Interventions
Oxycodone HCl controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Not applicable Interventional

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

NCT04003350
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Oxycodone, Tramadol, Tylenol, Meloxicam, Gabapentin, Metaxalone, Esomeprazole 20mg
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

NCT00361504
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
Interventions
Oxycodone CR, Tapentadol (CG5503) ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 18, 2026, 10:15 AM EDT
Enrolling by invitation Phase 3 Interventional

Reduce Opiate Exposure With ACL Surgery

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

NCT02716857
View directory record Official record
Conditions
Moderate-to-severe Chronic Low Back Pain
Interventions
Oxycodone extended-release, Placebo of oxycodone extended-release
Drug
Lead sponsor
Egalet Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery

NCT03319277
View directory record Official record
Conditions
Postoperative Pain, Opioid Use
Interventions
Decreased opiate prescription, Routine opiate prescription
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853268
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

NCT01369615
View directory record Official record
Conditions
Pain
Interventions
Oxycodone hydrochloride controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Paramount, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Postoperative Nudges to Reduce Opioid Prescribing

NCT05070338
View directory record Official record
Conditions
Opioid Prescribing
Interventions
Guideline-Based (Injunctive Norm) Nudges, Peer-Based (Social Norm) Nudges
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain

NCT00813488
View directory record Official record
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablet, Immediate release oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

NCT00463047
View directory record Official record
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

ICE-T Pain Regimen for Total Laparoscopic Hysterectomy

NCT03987022
View directory record Official record
Conditions
Opioid Substitution Treatment
Interventions
Ketorolac, Opioids, Ice Packs, Tylenol, Motrin, Dilaudid Injectable Product, Percocet 5Mg-325Mg Tablet
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

NCT03845881
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Oxycodone, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 18, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

NCT01160614
View directory record Official record
Conditions
Opioid Analgesia
Interventions
Oxycodone hydrochloride controlled-release (ORF) tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 18, 2026, 10:15 AM EDT
Withdrawn Phase 3 Interventional

Multimodal Analgesia in Shoulder Arthroplasty

NCT03586934
View directory record Official record
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 18, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

NSAID Use After Robotic Partial Nephrectomy

NCT05842044
View directory record Official record
Conditions
Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions
Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 18, 2026, 10:15 AM EDT